Research programme: cancer drug discovery - Dana-Farber Cancer Institute / Evotec SE
Latest Information Update: 25 Sep 2019
At a glance
- Originator Dana-Farber Cancer Institute; Evotec AG
- Developer Dana-Farber Cancer Institute; Evotec SE
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 30 Apr 2013 Early research in Cancer in USA (unspecified route)